This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Werner, N. S. Articles by Opalka, B. Search for Related Content PubMed PubMed Citation Articles by Werner, N. S. Articles by Opalka, B.

Differential Susceptibility of Renal Carcinoma Cell Lines to Tumor Suppression by Exogenous Fhit Expression¹

Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Westdeutsches Tumorzentrum Essen, 45122 Essen, Germany [N. S. W., G. M., J. K. S., W. B., S. S., J. S., B. O.], and Department of Microbiology and Immunology, Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania 19107 [Z. S., L. Y. Y. F., K. H.]

Hemizygous deletions of the fragile histidine triad (FHIT) gene at human chromosome band 3p14.2 and down-regulation of its gene product are found in the majority of renal cell carcinomas (RCCs). Functional tumor suppressive activity of Fhit in renal cancer cells previously was observed in RCC cell line RC48, which lacks endogenous Fhit expression. To further investigate the potential role of FHIT as a tumor suppressor gene in RCC, we transfected FHIT cDNA expression constructs into RCC cell lines RCC-1 and SN12C, which show low-level expression of endogenous Fhit and reveal an intact von Hippel-Lindau (VHL) gene. Stable transfectants of both cell lines showed no alterations of cell morphology, proliferation kinetics, or cell cycle parameters in vitro. The FHIT gene transfer rate, however, was significantly lower in RCC-1 cells compared with SN12C cells, suggesting a selection against exogenous Fhit expression. In addition, in nude mouse assays, a significant delay of tumor formation was observed for FHIT-transfected RCC-1 cell lines, with outgrowing tumors demonstrating loss of Fhit expression in the majority of cells. In contrast, tumorigenicity of FHIT-transfected SN12C cell clones was not suppressed, despite stable transgene expression. In conclusion, our results demonstrate a selective tumor suppressive activity of Fhit in RCC cells in vivo and suggest that the susceptibility to suppression is not restricted to cancer cells with complete loss of Fhit expression.

This article has been cited by other articles:

				F. Pichiorri, F. Trapasso, T. Palumbo, R. I. Aqeilan, A. Drusco, B. W. Blaser, D. Iliopoulos, M. A. Caligiuri, K. Huebner, and C. M. Croce Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35. Clin. Cancer Res., June 1, 2006; 12(11): 3494 - 3501. [Abstract] [Full Text] [PDF]

				N. Korsisaari, D. J. Rossi, K. Luukko, K. Huebner, M. Henkemeyer, and T. P. Makela The Histidine Triad Protein Hint Is Not Required for Murine Development or Cdk7 Function Mol. Cell. Biol., June 1, 2003; 23(11): 3929 - 3935. [Abstract] [Full Text] [PDF]

				F. Trapasso, A. Krakowiak, R. Cesari, J. Arkles, S. Yendamuri, H. Ishii, A. Vecchione, T. Kuroki, P. Bieganowski, H. C. Pace, et al. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding PNAS, February 18, 2003; 100(4): 1592 - 1597. [Abstract] [Full Text] [PDF]

				L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines PNAS, March 19, 2002; 99(6): 3615 - 3620. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				M. Velickovic, B. Delahunt, S. Storkel, and S. K. G. Grebem VHL and FHIT Locus Loss of Heterozygosity Is Common in All Renal Cancer Morphotypes But Differs in Pattern and Prognostic Significance Cancer Res., June 1, 2001; 61(12): 4815 - 4819. [Abstract] [Full Text] [PDF]

				K. R. Dumon, H. Ishii, A. Vecchione, F. Trapasso, G. Baldassarre, F. Chakrani, T. Druck, E. F. Rosato, N. N. Williams, R. Baffa, et al. Fragile Histidine Triad Expression Delays Tumor Development and Induces Apoptosis in Human Pancreatic Cancer Cancer Res., June 1, 2001; 61(12): 4827 - 4836. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, F. Trapasso, K. Mimori, H. Alder, M. Mori, G. Sozzi, R. Baffa, K. Huebner, et al. Effect of Adenoviral Transduction of the Fragile Histidine Triad Gene into Esophageal Cancer Cells Cancer Res., February 1, 2001; 61(4): 1578 - 1584. [Abstract] [Full Text]